lymphatic leukemia and more than 81/2 mo in blastic crisis of chronic myeloid leukemia. The corresponding median survival times in the latter patient group were 64, 135, and 90 days. These findings were unrelated to prognostic features already known.
INTRODUCTION
Many studies have suggested that human malignant cells possess antigenic determinants which can elicit specific immune responses from the host (1) (2) (3) (4) . In leukemia, tumor-associated antigens have been mainly detected by the use of xenoantisera to leukemic cells (5) (6) (7) (8) . Circulating antibodies, leukemic cell-bound immunoglobulins, and lymphocytes which had in vitro cytotoxicity for leukemic cells, have been found in patients with leukemia (9) (10) (11) (12) (13) .
Whether these immune reactions of the cancer patient play a role in vivo in the disease process is difficult to assess. It is obvious that they are most often insufficient to adequately control the malignant cell proliferation. Interference of humoral factors with the cell-mediated response of the patient to his neoplasm has been proposed as an explanation ofthe failure ofthe immume system to control tumor growth, and this is supported by the demonstration in vitro of a specific blocking of lymphocyte-mediated cytotoxicity by the serum of individuals with growing tumors (10, 14, 15) . There is evidence that serum blocking factors may consist of immune complexes (16) (17) (18) (19) . Furthermore, several studies have indicated that antigen-antibody complexes, possibly related to the tumor, may circulate in blood (18, (20) (21) (22) (23) (24) or be deposited in tissues (25) (26) (27) (28) of patients with different types of malignancy, including leukemia (29 The present study was carried out, using the [125I]-Clq-binding test (30) and the Raji cell radioassay (23) , to determine the incidence of circulating immune complexes in leukemia and to investigate their relationship to clinical and biological features of the disease and to prognosis. The serum Clq-binding material which was detected was further characterized by immunochemical and physical analysis.
MIETHODS
Patients. The patients included in this investigation were hospitalized in Roswell Park Mlemorial Institute, Buffalo, N. Y.; Hopital Edouardl Herriot, Lyon, France; Centre Hospitalier R6gional, Toulouse, France; Hopital Universitaire, Liege, Belgium; and the Hopital Cantonal, Geneva, Switzerland. Serumil samples were obtained from 100 patients with acute myeloi(d leukemia (ANML),' 39 patients with acute lymphatic leukemiiia (ALL), 28 patients in blastic crisis of chroniic mveloid leukemia, 38 patients with chronic mveloidl leukemia (CML), and 25 patients with chronic lymphatic leukemia (CLL). When possible, serial serum samples from patients were examined and the level of immune complexes was correlated with the clinical course of the disease. In acute leukemias (AML, ALL, and blastic crisis) 175 of the serum samples were taken from 110 patients at onset of the disease and 20 patients in relapse; the other 103 samples corresponded to the period of complete clinical remissioni. Sepsis was found in 41 (37%) of the patients tested at onset of acute leukemia and 6 patients (30%) examinied in relapse. Increased erythrocyte sedimentation rate was observed in 54.5% of patients in blastic phase, at the time of serum analysis. Most of the patients were treatedl by chemiiotherapy according to the type and the stage of leukemiiia. In addition, all except 8 of the 38 patients with CML were vacciniated with either bacille Calmette-Gu6rin (BCG) alone or BCG plus cultured allogeneic lymphoblastoid cells, accordling to the Sokal immunotherapy program (31) .
Collectiotn anid storage of sera. Blood was drawn aseptically from patients and( allowed to clot at room temperature or at 37°C for at least 60 min. It was then centrifuged at 1,500 g for 15 mmin without cooling, and the serum was stored at -70°C until used. Control sera from 68 healthy bloocl donors were collected in the same way.
Radiolabeled Clq-binidinig tests. Details of the technique have been previously described (30, 32, 33) . On the day of the test, a portion of radiolabeled Clq was diluted in 3-5 ml of Veronal-buffered saline containing 1% normal human serum pool-heated for 30 min at 56°C. It was then centrifuged at 18,000 g for 40 
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To test the dissociation at acid pH of the Clq-binding material, gradient fractions from a first ultracentrifuge run, which contained the Clq-binding material, were pooled. Equal volumes of this pool were mixed with 2 vol of either borate buffer, pH 8.3, or acetate buffer, pH 3.5, and left on ice for 2 h. 1 ml of each mixture was layered on a 4-ml sucrose density gradient ofcorresponding pH and centrifuged simultaneously at 271,000 g for 4 h at 10°C. Acid gradient fractions were neutralized immediately after their collection by addition of 0.5 M Tris-NaOH, pH 13, and left at room temperature for 60 min before being tested for their Clq-binding activity. In each experiment, a sample of diluted normal human serum was centrifuged in parallel in a control gradient tube. The 19s and 7s peaks of normal human serum OD pattern were used as gradient markers, and the apparent s values were calculated according to Martin and Ames (36) .
Immunochemical procedures. Immunoelectrophoresis on gradient fractions from ultracentrifugation was carried out according to the method of Scheidegger (37), using commercial rabbit anti-human IgG (y-chain) and rabbit antihuman IgM (,u-chain) sera (Behringwerke, Marburg/Lahn, West Germany). For immunoabsorption, rabbit anti-human IgG or bovine serum albumin (A-grade, Calbiochem, San Diego, Calif.) were coupled to AH-Sepharose 4B (Pharmacia, Uppsala, Sweden) activated by glutaraldehyde (25% aqueous solution, Serva, Heidelberg, West Germany) according to Cambiaso et al. (38) . Two identical 2-ml columns (1 cm diameter) were prepared at 4°C. They were washed with phosphate-buffered saline at pH 7.5. Clq-binding pooled gradient fractions were applied to each column, and the flow was stopped for 1 h. Unbound gradient fraction components were washed out by slowly pumping 4 ml of phosphatebuffered saline, pH 7.5, through each column. These effluents were concentrated to 0.5 ml of Diaflo ultrafiltration membrane (UM 10, Amicon Corp., Lexington, Mass.) in a microfiltration system (model 8 MC, Amicon Corp.). The concentrated effluents were then tested for their Clqbinding activity. IgG contents of the Clq-binding gradient fractions used for these experiments and of the effluents were quantitated by radial immunodiffusion.
Enzymatic and chemical treatment of sera. For deoxyribonuclease (DNase) treatment, 50 ,ul of DNase (deoxyribonuclease 1, Worthington Biochemical Corp., N. J.) at 1 mg/ml in Veronal-buffered saline was added to 50 Al of serum. The mixture was incubated at 37°C for 3 h before the Clq-binding test was carried out. Controls were incubated with 50 ,ul of Veronal-buffered saline alone.
For reduction and alkylation of the Clq-binding material, 100 ,ld of serum was incubated with 100 ,ul of 0.4 M 2-mercaptoethanol at room temperature for 1 h and thereafter with an additional 100 ,ul of 0.66 M iodoacetamide at 4°C for another hour. Similar serum samples were incubated with 100 ,ul of Veronal-buffered saline.
To control the reduction-alkylation procedure, 100 ,ul of normal human serum containing human aggregated immunoglobulins at 1.5 and 0.5 mg/ml were treated in the same way as the serum samples. The mixtures were dialyzed for 24 h against Veronal-buffered saline before testing for Clq-binding activity. Statistical analysis. The results were statistically evaluated by Student's t test, the chi-square test, linear regression analysis, and Spearman's correlation test.
RESULTS
Clq-binding test and Raji cell radioassay in leukemic patients. The Clq-binding activity of 467 sera results was also shown to be significant by linear regression analysis (r = 0.9107, P < 0.001) and by Spearman's correlation test (r = 0.7998, P < 0.001).
Characterization of the Clq-binding material in leukemia. To determine the size of the Clq-binding material, six sera from patients with AML, two from patients with ALL, three from patients with blastic crisis, one from a patient with CML, and three from patients with CLL were studied by ultracentrifugation analysis on 10-40% (wt/vol) sucrose density gradients.
The collected gradient fractions were tested for their Clq-binding activity. The Clq-binding material was recovered in fractions corresponding to a 10-30s molecular weight material. In gradient fractions obtained after centrifugation of normal serum, the Clqbinding activity was lower than 5%. Results of serum ultracentrifugation in two patients, one with CLL and the other with blastic crisis, are represented in Fig. 2 .
In 10 patients the Clq-binding material was partially purified and concentrated using polyethylene glycol precipitation of serum before ultracentrifugation. This procedure led to a three-to fourfold increase of the Clq-binding activity in 14-28s gradient fractions when compared with the Clq-binding activity obtained in the corresponding fractions from ultracentrifugation of the original sera. Density gradient studies with the concentrated material were carried out to investigate the effect of acid treatment on the Clqbinding material. Clq-binding gradient fractions were centrifuged in parallel runs on sucrose density gradients at pH 8.3 and pH 3.5.
The optical density patterns of the two gradients were compared (Fig. 3) . At pH 8.3, the optical density pattern showed two peaks: a small peak in the 7s position and a wide, large peak in the 14-30s region. The optical density pattern of the acid gradient gave a major peak in the 7s situation, two smaller peaks with maximum values at the 19s and 28s positions, and a fourth small peak before the 7s region. After neutralization of acid gradient fractions, fractions from both gradients were tested for their Clq-binding activity. Clq-binding material was still detected in 14-28s fractions from ultracentrifugation at pH 8 albumin (BSA). The Clq-binding activity of the effluents from both columns were compared. In the effluents from the anti-IgG column, only traces of Clq-binding material could be detected, whereas the Clq-binding activity of the effluents from the bovine serum albumin column was high (Table II) . The passage of the Clq-binding fractions through the antiIgG-Sepharose column resulted in a parallel decrease of the IgG content and of the Clq-binding activity, respectively, to 12% and 17% of the corresponding values obtained after passage through the bovine serum albumin column.
The effect of reduction-alkylation on the Clq-binding activity of leukemic sera was assessed. Treatment of 16 activity from 16±9% to 4±8% (P < 0.001). Similar effect was found after reduction-alkylation of aggregated human immunoglobulin used as control samples. presence of sepsis (Table IV) . The group with and the present study, the cytological variety of AML did not group without circulating immune complexes had simi-appear to influence the response rate observed in these lar sex and age distribution. In AML and ALL, analy-patients. The patient group without circulating imsis of response rate in patients separated into age mune complexes included 32 patients with acute groups revealed progressively poorer remission in-myeloblastic leukemia, 2 patients with acute myelocidence with increasing age, regardless of whether or monocytic leukemia, and 3 patients with acute pronot the patients had circulating immune complexes myelocytic leukemia. In the patients with detectable during the blastic stage (Fig. 5 ). Age and the presence circulating immune complexes, 26 had acute myeloof circulating immune complexes appeared as two blastic leukemia and 4 had acute myelomonocytic independent prognostic features which could be com-leukemia. Incidence of sepsis was almost the same bined for the assessment of the prognosis (Table V) . in the patients with immune complexes and those with The response to therapy of the patients with serum Clq-binding activity in the normal range (Table  circulating immune complexes was not related to IV). In patients without detectable immune complexes, unfavorable hematologic parameters (Table IV) : white presence of sepsis and bone marrow infiltration by blood cell count below 2,000 per mm3 or above leukemic cells above 75% at onset of leukemia were 50,000 per mm3, hemoglobin level less than 7 g/ associated with a poorer response rate. 100 ml, and platelet level under 100,000 per mm3. The
The individual survival times within the study degree of marrow infiltration by leukemic cells did period of the patients tested at the onset of disease not differ significantly between the patients with or were assessed (Fig. 6) . The median survival time without circulating immune complexes, except in the was 5 mo in patients with AML, more than 18 mo patients with ALL who responded to treatment. In the in the patients with ALL, and 5 mo in the pa- relation to the serum Clq-binding activity of the patients. The time interval between diagnosis and the serum sampling was short and did not influence these findings.
DISCUSSION
The occurrence of circulating immune complexes in cancer patients has been suggested first by the demonstration of serum blocking factors possibly related to immune complexes, and secondly by the direct detection of material similar to antigenantibody complexes in some patients with various types of malignancy (18, (20) (21) (22) (23) (24) (25) (26) (27) (28) 39) . In human leukemia, the presence of immune complexes has been suggested by the finding of renal glomerular deposits of Ig and complement in a few cases (29) . Serological studies using methods for direct detection of immune complexes have so far been limited (18, 23, 24, 27) .
The present data indicate that a material involving Ig and C3, and capable of reacting with Clq, may be present in relatively large amounts in the serum from many patients with acute leukemia. Physicochemical properties of this material indicate also that it may consist of circulating immune complexes. In density gradient experiments, the material sedimented as a 14-28s macromolecule, acid dissociation of which led to the appearance of a 7s peak containing IgG. Removal of IgG from the material either by immunoabsorption or by acid dissociation, or alteration of serum Ig molecules by a mild reduction-alkylation treatment, abolished the ability of the material to bind Clq. The possibility that some unknown polyanionic substances account for the serum Clq binding of some leukemic patients cannot be rules out. Interference of DNA in the present results was excluded, however, by the DNase treatment of the serum samples, and that of endotoxins or Creactive protein complexes by the test conditions.
The fact that the immune complexes were found mostly in sera from patients at the blastic stage of leukemia, regardless of the type of acute leukemia, should be considered in relation to the nature of antigens possibly involved in the complexes. The lack of correlation between the presence of immune complexes and evident sepsis in the patients minimizes the possibility of a bacterial origin of the complexed antigen. Clinically inapparent bacterial infections or slow virus infections may account, however, for formation of bacterial or viral antigen-antibody complexes. Thus, the course of the infection would be closely associated with the blastic stage of the leukemia, with a rapid disappearance during complete remission. Antibodies reacting with the major histocompatibility antigens, possibly induced by repeated blood transfusion, do not appear to be a major source of circulating immune complexes in leukemia. Antigens with a specificity unrelated to the leukemic cells, or related to the blastic state of the cells, may be considered. DNA anti-DNA (40) (44) (45) (46) . Correlation between the presence in serum of immune complexes and the blastic cell proliferation is also in agreement with a possible involvement of leukemia-associated antigens (5) (6) (7) (8) (9) (10) (11) (12) (13) 47) . However, the destruction of many malignant cells by chemotherapy does not increase the level of circulating immune complexes.
The clinical relevance of circulating immune complexes in patients with leukemia is still difficult to assess. These complexes may be a secondary phenomenon ofthe disease particularly associated with the most severe forms of leukemia. The occurrence and persistence of circulating immune complexes in some patients with acute leukemia may also reflect a particular immune status of these patients (48, 11) , since the persistence of antigen-antibody complexes may be favored by the production of antibodies of low avidity (49) or of low titer (50) . However, circulating immune complexes may favor the progression of leukemia by modulating the immune response of the host against the malignant cells. Indeed, antigenantibody complexes can enhance or suppress lymphocyte activation (51) (52) (53) (54) and modulate functions of B lymphocytes (55) or T lymphocytes (56) (57) (58) (59) (60) (61) (62) . In animals bearing growing tumors, at least some of the serum blocking factors consist of immune complexes (15) (16) (17) .
The present data show that patients with acute leukemia and circulating immune complexes have a worse prognosis than those without such complexes. It is proposed that the assessment of the prognosis in patients with acute leukemia would be improved by the determination ofthis new parameter in combination with some other classical prognostic factors (63) , such as the age of the patients.
